Department of Digestive Endoscopy, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Rev Esp Enferm Dig. 2011 Nov;103(11):576-81. doi: 10.4321/s1130-01082011001100004.
chronic radiation proctopathy (CRP) is associated with recurrent rectal bleeding and transfusional requirements. Argon plasma coagulation (APC) and hyperbaric oxygen therapy (HOT) have been shown to be effective in the control of CRP. No prospective comparisons have been reported between these treatments.
the aim was to evaluate the effectiveness, safety and impact on tissue toxicity of APC compared to HOT in patients with CRP.
a prospective study for evaluating treatment response was conducted. Patients with cervical cancer and CRP with rectal bleeding were recruited. They had not received previous treatment. Collected data included: demographics, previous radiation dosage, duration and severity of rectal bleeding. Hemoglobin, transfusional requirements, and tissue toxicity (SOMA LENT questionnaire) at baseline and at 1, 2, and 3 months follow up were recorded.
thirty-one patients were included, 14 in the APC group and 17 in the HOT group. No response was noted in 13 and 18% of patients in the APC and HOT group respectively (p = NS). At the 1 and 2 months follow-up, the APC group showed a significantly better response in terms of transfusional requirements (0.6 vs. 3.4 and 0.7 vs. 2.5) and tissue toxicity score (5.3 vs. 8.6 and 3.8 vs. 7.248). After 3 months, both groups showed further improvement in all parameters without significant differences between them.
APC and HOT were effective, safe and decreased the tissue toxicity scores in patients with CRP. However, response rate was higher and faster in the APC group.
慢性放射性直肠病(CRP)与复发性直肠出血和输血需求有关。氩等离子凝固(APC)和高压氧治疗(HOT)已被证明在 CRP 的控制中有效。尚未报告这些治疗之间的前瞻性比较。
旨在评估 APC 与 HOT 相比在 CRP 患者中的有效性、安全性和对组织毒性的影响。
进行了一项评估治疗反应的前瞻性研究。招募了患有宫颈癌和 CRP 并伴有直肠出血的患者。他们没有接受过先前的治疗。收集的数据包括:人口统计学、以前的放射剂量、直肠出血的持续时间和严重程度。血红蛋白、输血需求以及基线和随访 1、2 和 3 个月时的组织毒性(SOMA LENT 问卷)。
共纳入 31 例患者,APC 组 14 例,HOT 组 17 例。APC 和 HOT 组分别有 13%和 18%的患者无反应(p = NS)。在 1 个月和 2 个月随访时,APC 组在输血需求(0.6 对 3.4 和 0.7 对 2.5)和组织毒性评分(5.3 对 8.6 和 3.8 对 7.248)方面表现出更好的反应。3 个月后,两组在所有参数上均进一步改善,组间无显著差异。
APC 和 HOT 均有效、安全,可降低 CRP 患者的组织毒性评分。然而,APC 组的反应率更高且更快。